Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma
- 397 Downloads
The aim of this study was to evaluate the effect of Cabergoline on insulin sensitivity, inflammatory markers, and carotid intima media thickness in prolactinoma patients. Twenty-one female, newly diagnosed patients with prolactinoma were included in the study. None of the patients were treated previously. Cabergoline was given as treatment, starting with 0.5 mg/day and tapered necessarily. Blood samples were taken for prolactin, highly sensitive C-reactive protein, homocysteine, total cholesterol, low density lipoprotein (LDL) cholesterol, fasting glucose, insulin, and HOMA (homeostasis model assessment of insulin resistance) score was calculated, prior to and 6 months after starting treatment. The body mass index (BMI) was measured and carotid intima media thickness (CIMT) was evaluated for each patient prior to and 6 months after the treatment. The prolactin levels and LDL decreased significantly after cabergoline treatment. Insulin sensitivity improved independently from the decrease in prolactin levels and BMI. The significant decrease in homocysteine and hs-CRP was not related with the decrease in prolactin levels. The significant decrease in CIMT was independent from the decrease in prolactin levels, HOMA score, and BMI. Our data suggest that cabergoline treatment causes an improvement in insulin sensitivity and inflammatory markers and causes a decrease in CIMT independent from the decrease in prolactin, LDL cholesterol, and BMI. We conclude that short term cabergoline treatment can improve endothelial function independently from the changes in metabolic disturbances and inflammatory markers.
KeywordsProlactinoma Carotid intima media thickness Insulin resistance Inflammation Atherosclerosis
Conflict of interest
Authors declare no conflict of interest.
- 11.O. Serri, L. Li, J.C. Mamputu, M.C. Beauchamp, F. Maingrette, G. Renier, The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. (Oxf) 64(4), 366–370 (2006)Google Scholar
- 12.E.C. Naliato, A.H. Violante, D. Caldas, A. Lamounier Filho, C.R. Loureiro, R. Fontes, Y. Schrank, R.G. Souza, P.L. Costa, A. Colao, Body fat in nonobese women with prolactinoma treated with dopamine agonists. Clin. Endocrinol. (Oxf). 67(6), 845–852 (2007). Epub 2007 Jul 20PubMedCrossRefGoogle Scholar
- 15.A.Q. Reuwer, M. van Eijk, F.M. Houttuijn-Bloemendaal, C.M. van der Loos, N. Claessen, P. Teeling, J.J. Kastelein, J. Hamann, V. Goffin, J.H. von der Thüsen, M.T. Twickler, J. Aten, The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J. Endocrinol. 208(2), 107–117 (2011)PubMedCrossRefGoogle Scholar
- 17.G.A. Georgiopoulos, K.S. Stamatelopoulos, I. Lambrinoudaki, M. Lykka, K. Kyrkou, D. Rizos, M. Creatsa, G. Christodoulakos, M. Alevizaki, P.P. Sfikakis, C. Papamichael, Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54(1), 98–105 (2009). Epub 2009 May 18PubMedCrossRefGoogle Scholar
- 30.V. Kamath, C.N. Jones, J.C. Yip, B.B. Varasteh, A.H. Cincotta, G.M. Reaven, Y.D. Chen, Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose, insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemic women. Diabetes Care 20(11), 1697–1701 (1997)PubMedCrossRefGoogle Scholar
- 32.H. Wallaschofski, A. Kobsar, O. Sokolova, M. Eigenthaler, T. Lohmann, Co-activation of platelets by prolactin or leptin—pathophysiological findings and clinical implications. Hormone Metab. Res. 36(1–6), 99 (2004)Google Scholar